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Abstract
Background: There is considerable evidence from the literature that children with chronic lung
disease of infancy (CLD) have abnormal pulmonary function in childhood and this could have an
impact on their life quality and overall health. There are similarities between CLD and asthma, and
corticosteroids are the mainstay treatment for asthma. Many physicians use inhaled corticosteroids
in children with CLD with no evidence. Therefore we wish to conduct a randomized double-
blinded placebo controlled trial to test for the role of inhaled corticosteroids in children aged
from3 to 9 years with a history of CLD. Our primary hypothesis will be that inhaled corticosteroids
are beneficial in children with CLD.
Methods: Our primary hypothesis is that using inhaled steroids; Beclomethasone Dipropionate
(QVAR) 100 mcg 2 puffs 2 times a day for 6 weeks will improve the respiratory system resistance
and the quality of life in children with CLD.
Discussion: We propose that Beclomethasone Dipropionate (QVAR) will affect the pulmonary
function after 6 weeks of treatment. In summary we think that our study will highlight knowledge
on whether the use of inhaled steroids is clinically effective for CLD.
Background
Children with a history of severe CLD were left with sig-
nificant pulmonary sequelae at school age compared with
prematurely born children who had required ventilator
assistance and supplemental oxygen in the neonatal
period but who did not go on to have CLD [1]. It was also
documented that prematurely born children with respira-
tory distress syndrome (RDS) have long term pulmonary
sequelae consisting of airway obstruction and airway
hyper reactivity, which are related to both the severity of
the initial pulmonary insult and its treatment as well as to
a familial predisposition to airway hyper reactivity. The
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role of inhaled corticosteroids in children with chronic
lung disease of infancy or bronchopulmonary dysplasia
was not previously studied although most if not all physi-
cians use this treatment for these children whenever they
develop chest infections or wheezy episodes. This is a ran-
domized double blinded placebo controlled study using
inhaled corticosteroid (CFC free Beclomethasone dipropi-
onate, QVAR) for 6 weeks and measuring the effect on
pulmonary function and quality of life.
Methods
We will use a double blind randomized parallel design.
Patients will be invited to the study by sending a letter
from the perinatal clinic office inviting them to contact us.
Consent will be handed to the parents at the beginning of
the study. Subject randomization will be carried out using
a computer generated random numbers. Medications and
placebo will be kept locked in a cabinet in the clinic area,
one of the clinic nurses will be responsible for dispensing
the medication or placebo. The medication or placebo
will be taken twice daily, at 08:00 and 20:00. The Placebo
will have the same taste, shape and color of the study
drug. There will be a run in period for 1 week before the
study, for teaching the patients, and checking proper tech-
nique, and filling out the Child Health Questionnaire
(CHQ). In the first visit, informed consent filled, inclu-
sion and exclusion criteria will be obtained. Medical and
surgical history, physical exam, inhalation and pulmo-
nary function technique will be done. We will review the
daily diary, and prepare the placebo for all patients in the
run in period. One week after the run in period, randomi-
zation carried out and patients entered into the study.
Phone calls will be carried out every two weeks to opti-
mize compliance. After six weeks of treatment, CHQ will
be filled. Forced expiratory volume at 1 second (FEV1)
(for children older than 6 years of age) and respiratory sys-
tem resistance at 5 Hz frequencies will be measured.
The Impulse Oscillometry tool to be used is developed by
Jaeger Company (Wurzburg, Germany). In short rectan-
gular mechanical impulses containing the whole fre-
quency spectrum are applied to the respiratory system by
a mouthpiece, while the patient is breathing quietly. The
resulting pressure and volume signals are analysed for
their amplitude and phase difference to determine the Rrs
at 5 Hz of the total respiratory system [2]. One investiga-
tor will perform all pulmonary function tests. After a short
explanation, the children will perform some practice tri-
als. When the child is feeling comfortable, a measurement
of 25–35 seconds will be started. Patients will be asked to
breathe quietly through a round mouthpiece. A nose clip
will be used and the cheeks will be supported by the
hands of the investigator to minimize pressure loss
through the upper airway shunt. Measurement will be dis-
carded if the time-flow pattern showed apnea, speaking,
swallowing or air leak, as described by Bisgraaed and Klug.
The following parameter Rrs at 5 Hz will be recorded
before and 20 minutes after administration of 200 mcg
salbutamol. The spacer device used to administer the
medication will be an aerochamber with mask for chil-
dren under the age of 4.7 yrs old and with a mouth piece
for children above the age of 4.7 yrs [3-5].
The Study of a patient should be delayed six weeks if
developed a viral respiratory illness. Bronchodilators
should not be used on the day of the study visit (at least
24 hours for long acting, 6 hours for short acting). Neona-
tal variables to be collected from medical records: gender,
birth weight, birth length, head circumference, gestational
age, neonatal treatment, total days on oxygen, maximal
FiO2, days on CPAP, days on IPPV, use of steroids (how
much and how long), and the use of surfactant. Maternal
data: parity, living offspring's, and smoking days during
pregnancy. Skin prick testing for the 10 common allergens
will be done at the start of the study. Atopy will be defined
by one or more positive reactions (3 mm wheal) to 10
common aeroallergens. Parents will fill out daily symp-
tom scores. Social and environmental data to be collected
are smoking habits, pets, family history of asthma and
asthma in the child. Methacholine challenge testing will
be done in the start of the study to define those patients
with airway hyper reactivity, which might be a sensitive
indicator of response to steroids [6,7]. Respiratory func-
tion will be measured using Spirometry (FEV1) and
Impulse Oscillometry (RS @ 5 Hz). Quality of life will be
measured using the CHQ. Treatment group will receive
QVAR 100 mcg 2 puffs twice daily; placebo will be given
to the other arm for 6 weeks, after which the respiratory
function and quality of life will be measured.
Aim of the study
To study the effect of inhaled steroids on school- aged
children with CLD.
Primary hypothesis
Inhaled corticosteroids, Beclomethasone Dipropionate
will improve respiratory system resistance after 6 weeks of
treatment.
Primary outcome measures
Improvement in respiratory system resistance at 5 Hz fre-
quency measured by impulse oscillometry after 6 weeks of
inhaled corticosteroids in CLD.
Secondary outcome measures
Improvement in Quality of life system score using Child
Health Questionnaire (CHQ) and FEV1 response to bron-
chodilators (Salbutamol) after inhaled corticosteroids
treatment for 6 weeks in children with CLD.BMC Pulmonary Medicine 2005, 5:6 http://www.biomedcentral.com/1471-2466/5/6
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The inclusion criteria: children between 3 and 9 years of
age with a history of CLD with the following criteria.
1. Premature birth at 36 weeks gestation or less.
2. Clinical and radiological diagnosis of CLD. Patient
charts will be reviewed and the x-rays will be reviewed,
even if there is no x-ray findings patients will be included
if they fulfil the other criteria.
3. Requirement of supplemental oxygen to maintain satu-
ration of 90%, for at least 36 wk corrected gestation.
The exclusion criteria:
1. Cardiovascular disease other than PDA (Patent Ductus
Arteriosus)
2. Those with severe neurological disease, developmental
delay. Oxygen requirement for respiratory diagnosis other
than CLD e.g. congenital diaphragmatic hernia and aspi-
ration. An inability to perform spirometry or IOS, or non-
compliance with therapy and those with pneumonia.
Statistical consideration
The required number of patients was estimated as n = 74
(37 in each group) and to allow 10% dropout we need 82
patients. The sample size estimation was based on a type
I error rate of = .05 and a type II error rate of = 0.20. The
improvement in airway resistance at 5 HZ as primary end
point was expected to be 15% for the treatment group.
The coefficient variation for the impulse oscillometry
measurement is 10%. The primary statistical analysis of
efficacy data is based on the intention-to-treat patients,
who were randomly assigned to treatment and received at
least one dose of medication. Baseline characteristics will
be compared using descriptive statistics including confi-
dence intervals. Imbalance between the groups on key var-
iables, which might influence the observed outcome, will
indicate that an adjusted analysis is necessary using these
variables. The differences between airway resistance at 5
HZ response will be tested with a 2-tailed paired test on a
significance level of = .05. Analysis of FEV1 improvement
will be performed by two-tailed T test (= .05). All tests,
except those for CHQ, will be done by SSPS procedures.
For CHQ analysis, the differences of sum scores at week 6
after treatment to baseline will be tested by Wilcoxon rank
sum test using StatXa.
Discussion
Bronchopulmonary Dysplasia (BPD) is a chronic lung dis-
ease related to injury induced by mechanical ventilation
and oxygen therapy in prematurely born infants. William
Northway, a radiologist at Stanford University, described
this pathology in 1967[8]. More recently the term chronic
lung disease (CLD) has been used since nowadays pre-
term infants with birth weights between 500 and 750
grams have at least a 50 percent chance of survival at 24
weeks gestation age[9]. The clinical diagnosis of this CLD
is made at one month of age in prematurely born infants
who have undergone mechanical ventilation for at least
one week, who have symptoms of persistent respiratory
distress, are dependent on supplemental oxygen, and who
have chest radiographs that show rounded radio lucent
areas in the lung alternating with thinner strands of radi-
odensity.
The pathogenesis of CLD is believed to be multifactorial,
with pulmonary oxygen toxicity and barotrauma having
important roles [10]. More recently inflammatory media-
tors, cytokines, and proteolytic enzymes released by
inflammatory cells, whose influx into the lungs is the con-
sequence of oxygen exposure and prenatal or postnatal
sepsis, were described [11]. The release of neuropeptides
such as substance P from afferent nerve endings in the air-
ways or lung parenchyma may accelerate this inflamma-
tory cascade[12]. Coates et al found decreased expiratory
flows in children 7 and 8 years old who had survived the
respiratory distress syndrome, and later suggested that
oxygen therapy could have been at least partly responsible
for these sequelae [13]. CLD has become the most com-
mon form of chronic lung disease in infants in the United
States with approximately 7000 new cases occurring each
year [14].
It has been noted that infants with BPD were twice as
likely to be hospitalized in the first 2 years of life com-
pared with preterm infants without BPD [15]. But at age 7
years both groups had more cough and wheeze than the
term group. Pulmonary function including lung volumes
and expiratory airflow were worse in the BPD group. This
group showed more evidence of gas trapping and hyper-
inflation and significant expiratory airflow obstruction
[15]. This was confirmed by the study done by Jacob et al
who compared children of BPD at 11 years old with chil-
dren in a control group who were born preterm but who
did not have BPD [9]. This was also supported by the find-
ings of Coates et al who confirmed that premature birth
and the development of the RDS of the newborn have
been associated with long term pulmonary sequelae
[13,16]. Is there any treatment available for those chil-
dren?
The literature suggested that there is significant morbidity
and mortality from chronic lung disease in infancy into
adult and elderly ages. In a follow up study of men born
during 1911–1930 whose birth weight, weight at 1 year,
and childhood respiratory illnesses were recorded at that
time by health visitors [17], Barker et al found that lower
birth weight was associated with worse adult lung func-BMC Pulmonary Medicine 2005, 5:6 http://www.biomedcentral.com/1471-2466/5/6
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tion. Bronchitis, pneumonia, or whooping cough in
infancy further reduced adult lung function, they con-
cluded that death rates from chronic obstructive disease,
but not from another disease related to smoking or lung
cancer fell with increasing birth weight and weight at 1
year. This was supported by the findings of Peto et al [18]
in their follow up study of men whose lung function and
respiratory symptoms had been assessed in adult life and
showed that the risk of death from chronic obstructive air-
way disease was strongly correlated with the initial FEV1.
Liggins and Howie have demonstrated that the adminis-
tration of a corticosteroid leads to a decreased incidence of
RDS in human premature infants[19]. It is well known
that inhaled and systemic steroids are used for the preven-
tion of CLD in infancy [20]. Any pulmonary growth retar-
dation would be expected to have an effect on the airways
and result in increased airway resistance and lower flows.
It was pointed out that the only major changes in airways
from birth to adulthood are in their size [21]. High inci-
dence of asthma has been noted in families of neonates in
whom the RDS was complicated by CLD [22]. Other clin-
ical studies suggest an increased incidence of airway hyper
reactivity in prematurely born children [23-26]. Recurrent
wheeze in childhood and readmission to hospital for
bronchiolitis like illness has been observed among prema-
turely born children who survived the RDS [24]. Most
patients with CLD also have increased airway lability and
improvement in expiratory flow rates following bron-
chodilator inhalation suggesting that such therapy may
improve pulmonary function in these children [15]. It was
anticipated that the incidence of CLD would decrease after
the introduction of surfactant therapy, clinical trials by
Horbar and Long failed to confirm this [27,28].
So far there are no studies have been published studying
the clinical response to inhaled corticosteroids in children
CLD. Pulmonary function testing for these children can be
done using different techniques. Pennings et al [29] used
forced oscillation technique (FOT) to detect changes in
airway bronchial tone of asthmatic patients, that were not
detected by conventional flow volume recording. It was
found that the changes of the diameter of small airways of
children could be missed by routine spirometry. The
apparent increase incidence of bronchiolitis in RDS survi-
vor's points to these small airways as a source of pathol-
ogy [30]. In 1956, Dubios et al described the use of FOT
as a measure of total respiratory system impedance, which
was non invasive and required minimal cooperation from
the subject and it can be applied to infants and older chil-
dren. Laberge et al used FOT to measure respiratory sys-
tem resistance in 3 to 6 years old asthmatic children and
they concluded that the dry powder inhaler (Turbuhaler)
and the metered dose inhaler with spacer (Nebuhaler) are
equally effective in administering terbutaline [31].
Conclusion
We propose that Beclomethasone Dipropionate (QVAR)
will affect the pulmonary function after 6 weeks of treat-
ment. In summary we think that our study will highlight
knowledge on whether the use of inhaled steroids is clin-
ically effective for CLD. This study was approved by the
conjoint Health Research Ethics Board and Child Health
Research Committee at the University of Calgary, Alberta,
Canada.
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